 Home > Active Ingredient News > Immunology News > ARD: Tocilizumab in New-Onset Polymyalgia Rheumatica (PMR-SPARE): A Phase 2/3 Randomized Controlled Trial

ARD: Tocilizumab in New-Onset Polymyalgia Rheumatica (PMR-SPARE): A Phase 2/3 Randomized Controlled Trial

 Last Update: 2022-08-16
 Source: Internet
 Author: User

Tags

study time space

inflammatory eye disease

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Objective : Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in people over 50 years of ag.

Objectives Objective : Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in people over 50 years of ag.

Methods : In this double-blind, multicenter Phase 2/3 clinical trial, the research team randomly assigned 36 patients with new-onset polymyalgia rheumatica from three centers to receive subcutaneous injection of anti-IL-6 tocilizumab ( 162 mg per week ) or placebo for 16 weeks ( 1:1 ratio.

Methods In this double-blind, multicenter Phase 2/3 clinical trial, the research team randomly assigned 36 patients with new-onset polymyalgia rheumatica from three centers to receive subcutaneous injections of anti-IL-6 tocilizumab (each 162 mg per week ) or placebo for 16 weeks ( 1:1 ratio.

Results From November 20 , 2017 , to October 28 , 2019 , 39 patients were screened for eligibility; 19 patients received tocilizumab and 17 patients received placeb.

Conclusions In patients with new-onset polymyalgia rheumatica who received rapid glucocorticoid tapering, tocilizumab was superior to placebo for sustained glucocorticoid-free remission, time to relapse, and cumulative glucocorticoid do.

Source: Bonelli M, Radner H, Kerschbaumer A , et a.
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled tri.
Annals of the Rheumatic Diseases2022;81:838-84 , et al Annals of the Rheumatic Diseasesleave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top Quality 99.9% Ritlecitinib Tosylate Immunoregulation API & Inflammation Inhibitor

CAS No.: 2192215-81-7

Pharmacy Grade; Food Grade

$200-250/G FOB

β-Alanine107-95-9

CAS No.: 107-95-9

$1-1.1/KG FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.